Enquirer Consulting Group

Reachable Buyer Map

Prepared for Madhu Gautam · Blue Jet Healthcare · August 2026
In this category, first contact usually happens through a technical audit, a distributor, or a customer who qualified the plant years ago and told someone else about it. All three reach buyers who are already on a list somewhere. This map is the rest of the buying side in the United States, scoped there because that is where the largest share of the qualifying and buying for these chemistries sits, and counted from public registers rather than a database: the segments that purchase intermediates, sweeteners and contract manufacturing, who signs inside each one, and roughly how many sit there.
Contrast media and diagnostic agent makers
The smallest segment on the page and the most consequential, because qualifying a second source in iodinated or gadolinium chemistry is a supply security decision taken at group level rather than a purchasing one. Small enough to be worked name by name instead of as a list, which is also why it is almost never worked at all.
Who signs: the head of global sourcing, VP of technical operations, the supply chain risk lead, and the quality head who owns the audit.
Roughly 20 to 40
US registered establishments working in diagnostic and imaging agents, out of roughly 9,800 registered drug establishments nationally
Generic and specialty drug manufacturers
The volume buyer of intermediates and active ingredients. Second sourcing here is a standing program rather than an event, and qualification runs on documentation and audit history long before it runs on chemistry or price.
Who signs: VP of procurement or strategic sourcing, the head of chemistry and manufacturing controls, the director of supply chain, the quality assurance head.
1,500 to 2,500
US drug establishments formulating or manufacturing finished doses
Peptide and metabolic drug developers
The fastest moving buyer of protected amino acids, because a peptide program goes from grams to commercial volumes in a hurry once it reads out, and the supply decision is usually taken before the approval lands. Worth being straight about a limit: no public register records which companies run peptide chemistry, so this band is estimated from published pipelines rather than counted.
Who signs: the chief technical officer, head of chemistry and manufacturing controls, VP of manufacturing, and the chief executive on a first commercial supply agreement.
Roughly 300 to 600
US developers with peptide or metabolic programs in clinical development; estimated from public pipelines, not registered
Contract development and manufacturing organizations
They buy intermediates on behalf of their own customers, so one approval can reach several programs at once. Also the segment most willing to treat a supplier as a named partner on a filing, which makes the relationship harder to displace once it exists.
Who signs: the head of procurement, the site technical director, the business development lead, the quality head.
400 to 700
US establishments offering contract development or manufacturing of drug substances
Food, beverage and oral care formulators
The sweetener side, and a genuinely separate market with no shared list. Sugar reduction is a reformulation project with a marketing date attached, so it moves faster than pharmaceutical sourcing and is decided further from the plant. Stated plainly: no register records which manufacturers formulate sugar free, so this band is a sector count rather than a buyer count.
Who signs: the director of research and development, the head of procurement, the category technical lead, and the regulatory manager on a label change.
1,200 to 2,000
US food, beverage and oral care manufacturers at 100 people or more

Where the openings are

1
Two markets buy from the same plant and never meet. Pharmaceutical sourcing and food reformulation sit in different companies, read different publications and answer to different regulators. One channel written for both will land properly with neither, which is a copy problem before it is a list problem.
2
The buying event is a qualification, not an order. A second source review, a supply diversification push, a capacity announcement, a filing that names a new supplier. Those moments are visible from outside if someone is watching the whole market, and invisible if the plan is to wait for an audit request to arrive.
3
The two smallest segments are the most valuable. Roughly 20 to 40 imaging agent establishments and 300 to 600 peptide developers are small enough to reach individually by name, and each one is a multi-year relationship rather than a purchase order. Nobody works a list that short with a machine, which is precisely why it stays open.
4
Five segments, roughly 3,420 to 5,840 US organizations. Large enough to be worth working systematically, small enough that a channel built on named roles can cover it inside a year. That is a distribution gap rather than a credibility one, and it is the part we build, run in market, and hand over when it works.
Built from public federal registers of United States drug establishments and from public employer filings covering United States food, beverage and oral care sites, current to the most recent published year. Counts are banded deliberately. They describe registered establishments rather than companies, so a firm with three sites appears three times, and segment splits are estimated from registration codes rather than from any private database. Peptide programs and sweetener use are not recorded in any register anywhere and are estimated rather than counted. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com